Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Paclitaxel

Discovered in the 1960s in the bark of the Pacific yew (Taxus brevifolia) by Monroe Wall and Mansukh Wani, who published its structure in 1971. Approved as a cancer medicine in 1992, it is now made by semi-synthesis from the needles of the European yew or by plant cell culture. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards, nitrosamines and other impurities.

Did you know?The yew is one of the most poisonous trees in our woods: almost every part of it is toxic. Yet it gave us one of the cancer medicines that have saved the most lives.

PaclitaxelGo to the active ingredient →
PaclitaxelActive ingredientPaclitaxelCat. No. P-P001-001CAS 33069-62-4
Paclitaxel-d5Isotopically labelledPaclitaxel-d5Cat. No. P-P001-022CAS 1129540-33-5
TaxaneImpurityTaxaneCat. No. P-P001-093CAS 1605-68-1

EDQM standards 5

The official European Pharmacopoeia standards for this family.

Reference substancePaclitaxel CRSEDQM code Y0000698Family Paclitaxel

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.